Astria Therapeutics, Inc. (ATXS) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Operating expenses:
Research and development	34.4	31.9	34.3	30.4	26.5	23.3	15.6	15.6
General and administrative	20.9	19.7	19.2	18.4	17.8	17.0	14.8	14.2
Total operating expenses	55.3	51.6	53.5	48.7	44.2	40.3	195.0	194.4
Loss from operations	-55.3	-51.6	-53.5	-48.7	-44.2	-40.3	-195.0	-194.4

Other income (expense):
Interest and investment income	6.3	4.0	1.7	0.7	0.3	0.2	0.1	0.1
Other expense, net	-0.1	-0.1	-0.1	-0.1	0.0	0.0	-0.1	0.0
Total other income, net	6.3	3.9	1.7	0.7	0.3	0.1	0.0	0.0
Net loss	-49.0	-47.7	-51.8	-48.1	-43.9	-40.2	-194.9	-194.4

Net loss per share attributable to common shareholders - basic	($2.36)	($2.77)	($3.55)	$0.32	$0.58	($3.89)	($48.31)	($54.18)
Net loss per share attributable to common shareholders - diluted	($2.36)	($2.77)	($3.55)	$0.32	$0.58	($3.89)	($48.31)	($54.18)

Weighted-average common shares outstanding used in net loss per share - basic	21.1	17.3	13.6	12.2	11.9	10.2	7.9	6.4
Weighted-average common shares outstanding used in net loss per share - diluted	21.1	17.3	13.6	12.2	11.9	10.2	7.9	6.4